World's Best Scientists 2026 revealed!

D-Index & Metrics

Microbiology

D-Index
54
Citations
9838
World Ranking
3979
National Ranking
119

Antonio Rivero publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Antonio Rivero sits on this spectrum.

55–64 publications: 8 scientists 65–74 publications: 29 scientists 75–84 publications: 55 scientists 85–94 publications: 112 scientists 95–104 publications: 137 scientists 105–114 publications: 190 scientists 115–124 publications: 235 scientists 125–134 publications: 234 scientists 135–144 publications: 288 scientists 145–154 publications: 264 scientists 155–164 publications: 264 scientists 165–174 publications: 253 scientists 175–184 publications: 276 scientists 185–194 publications: 190 scientists 195–204 publications: 233 scientists 205–214 publications: 207 scientists 215–224 publications: 198 scientists 225–234 publications: 155 scientists 235–244 publications: 161 scientists 245–254 publications: 160 scientists 255–264 publications: 146 scientists 265–274 publications: 139 scientists 275–284 publications: 148 scientists 285–294 publications: 115 scientists 295–304 publications: 96 scientists 305–314 publications: 88 scientists 315–324 publications: 106 scientists 325–334 publications: 65 scientists 335–344 publications: 76 scientists 345–354 publications: 64 scientists 355–364 publications: 62 scientists 365–374 publications: 65 scientists 375–384 publications: 61 scientists 385–394 publications: 34 scientists 395–404 publications: 44 scientists 405–414 publications: 36 scientists 415–424 publications: 35 scientists 425–434 publications: 29 scientists 435–444 publications: 33 scientists 445–454 publications: 34 scientists 455–464 publications: 25 scientists 465–474 publications: 26 scientists 475–484 publications: 20 scientists 485–494 publications: 19 scientists 495–504 publications: 16 scientists 505–514 publications: 17 scientists 515–524 publications: 23 scientists 525–534 publications: 14 scientists 535–544 publications: 14 scientists 545–554 publications: 18 scientists 555–564 publications: 12 scientists 565–574 publications: 7 scientists 575–584 publications: 9 scientists 585–594 publications: 9 scientists 595–604 publications: 9 scientists 605–614 publications: 7 scientists 615–624 publications: 9 scientists 625–634 publications: 7 scientists 635–644 publications: 4 scientists 645–654 publications: 5 scientists 655–664 publications: 6 scientists 665–674 publications: 7 scientists 675–678 publications: 3 scientists 679+ publications: 99 scientists
55 publications 679+

This scientist: 346 publications — 84th percentile

84% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 679 publications or more.

Antonio Rivero D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Antonio Rivero sits on this spectrum.

40 D-Index: 30 scientists 41 D-Index: 86 scientists 42 D-Index: 90 scientists 43 D-Index: 117 scientists 44 D-Index: 122 scientists 45 D-Index: 123 scientists 46 D-Index: 108 scientists 47 D-Index: 110 scientists 48 D-Index: 106 scientists 49 D-Index: 109 scientists 50 D-Index: 129 scientists 51 D-Index: 111 scientists 52 D-Index: 116 scientists 53 D-Index: 127 scientists 54 D-Index: 134 scientists 55 D-Index: 134 scientists 56 D-Index: 111 scientists 57 D-Index: 136 scientists 58 D-Index: 162 scientists 59 D-Index: 151 scientists 60 D-Index: 139 scientists 61 D-Index: 122 scientists 62 D-Index: 126 scientists 63 D-Index: 144 scientists 64 D-Index: 109 scientists 65 D-Index: 103 scientists 66 D-Index: 124 scientists 67 D-Index: 112 scientists 68 D-Index: 103 scientists 69 D-Index: 131 scientists 70 D-Index: 93 scientists 71 D-Index: 93 scientists 72 D-Index: 96 scientists 73 D-Index: 92 scientists 74 D-Index: 80 scientists 75 D-Index: 66 scientists 76 D-Index: 87 scientists 77 D-Index: 60 scientists 78 D-Index: 73 scientists 79 D-Index: 59 scientists 80 D-Index: 57 scientists 81 D-Index: 55 scientists 82 D-Index: 47 scientists 83 D-Index: 77 scientists 84 D-Index: 50 scientists 85 D-Index: 45 scientists 86 D-Index: 42 scientists 87 D-Index: 41 scientists 88 D-Index: 32 scientists 89 D-Index: 38 scientists 90 D-Index: 35 scientists 91 D-Index: 34 scientists 92 D-Index: 27 scientists 93 D-Index: 26 scientists 94 D-Index: 33 scientists 95 D-Index: 22 scientists 96 D-Index: 37 scientists 97 D-Index: 22 scientists 98 D-Index: 21 scientists 99 D-Index: 22 scientists 100 D-Index: 30 scientists 101 D-Index: 16 scientists 102 D-Index: 20 scientists 103 D-Index: 17 scientists 104 D-Index: 19 scientists 105 D-Index: 16 scientists 106 D-Index: 19 scientists 107 D-Index: 18 scientists 108 D-Index: 14 scientists 109 D-Index: 10 scientists 110 D-Index: 9 scientists 111 D-Index: 7 scientists 112 D-Index: 11 scientists 113 D-Index: 6 scientists 114 D-Index: 15 scientists 115 D-Index: 10 scientists 116 D-Index: 12 scientists 117 D-Index: 7 scientists 118 D-Index: 10 scientists 119 D-Index: 10 scientists 120 D-Index: 11 scientists 121 D-Index: 2 scientists 122 D-Index: 7 scientists 123 D-Index: 12 scientists 124 D-Index: 5 scientists 125 D-Index: 9 scientists 126 D-Index: 6 scientists 127+ D-Index: 95 scientists
40 D-Index 127+

This scientist: 54 D-Index — 29th percentile

29% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 127 D-Index or more.

Overview

Antonio Rivero is affiliated with the Instituto Maimónides de Investigación Biomédica de Córdoba in Spain. Their research primarily focuses on Medicine, with a significant number of publications in the subfields of Hepatology, Infectious Diseases, Epidemiology, Virology, and Emergency Medicine.

The scientist's recent papers cover several topics related to viral infections and immunology. Notable publications include:

  • Orthohepevirus C infection as an emerging cause of acute hepatitis in Spain: First report in Europe, 2022, Journal of Hepatology
  • Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study, 2020, The Lancet HIV
  • Development and Clinical Validation of a Pangenotypic PCR-Based Assay for the Detection and Quantification of Hepatitis E Virus ( Orthohepevirus A Genus), 2020, Journal of Clinical Microbiology
  • Serological and molecular survey of hepatitis E virus in cats and dogs in Spain, 2021, Transboundary and Emerging Diseases
  • Severe immunosuppression is related to poorer immunogenicity to SARS-CoV-2 vaccines among people living with HIV, 2022, Clinical Microbiology and Infection

Antonio Rivero has collaborated frequently with a group of co-authors including:

  • Antonio Rivero-Juárez
  • Javier Caballero-Gómez
  • Pedro López-López
  • Mario Frías
  • Juan Macías

Their work has been published in several scientific venues with repeated contributions to:

  • Transboundary and Emerging Diseases
  • Clinical Infectious Diseases
  • Journal of Antimicrobial Chemotherapy
  • One Health
  • Clinical Microbiology and Infection

Research topics addressed by Antonio Rivero include:

  • Hepatitis Viruses Studies and Epidemiology
  • Viral gastroenteritis research and epidemiology
  • Hepatitis C virus research
  • Liver Disease and Transplantation
  • HIV/AIDS Research and Interventions
  • HIV/AIDS drug development and treatment
  • HIV Research and Treatment

Antonio Rivero's scientific contributions concentrate on the epidemiology and clinical aspects of viral hepatitis and HIV, as well as diagnostic developments for viral infections. Their research involves both human and animal health perspectives, linking viral hepatitis studies in populations with broader One Health approaches.

Best Publications

  • Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.

    Kathleen Squires;Adriano Lazzarin;José M. Gatell;William G. Powderly

  • Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus.

    Juan Macías;Juan Berenguer;Miguel A. Japón;José A. Girón

  • Allograft Rejection Predicts the Occurrence of Late-Onset Cytomegalovirus (CMV) Disease among CMV-Mismatched Solid Organ Transplant Patients Receiving Prophylaxis with Oral Ganciclovir

    Raymund R. Razonable;Antonio Rivero;Aurelio Rodriguez;Jennie Wilson

  • Clinical progression of hepatitis C virus–related chronic liver disease in human immunodeficiency virus–infected patients undergoing highly active antiretroviral therapy

    Juan A. Pineda;José A. García-García;Manuela Aguilar-Guisado;María J. Ríos-Villegas

  • Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial

    Mark Sulkowski;Stanislas Pol;Josep Mallolas;Hugo Fainboim

  • The Use of Transient Elastometry for Assessing Liver Fibrosis in Patients with HIV and Hepatitis C Virus Coinfection

    Salvador Vergara;Juan Macías;Antonio Rivero;Alicia Gutiérrez-Valencia

  • Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors

    Antonio Rivero;José A. Mira;Juan A. Pineda

  • Selective reactivation of human herpesvirus 6 variant a occurs in critically ill immunocompetent hosts.

    Raymund R. Razonable;Cara Fanning;Robert A. Brown;Mark J. Espy

  • Prediction of Response to Pegylated Interferon plus Ribavirin by IL28B Gene Variation in Patients Coinfected with HIV and Hepatitis C Virus

    Juan A. Pineda;Antonio Caruz;Antonio Rivero;Karin Neukam

  • Dual treatment with atazanavir–ritonavir plus lamivudine versus triple treatment with atazanavir–ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

    José A Perez-Molina;Rafael Rubio;Antonio Rivero;Juan Pasquau

  • High rate of tuberculosis reinfection during a nosocomial outbreak of multidrug-resistant tuberculosis caused by Mycobacterium bovis strain B.

    Antonio Rivero;Manuel Márquez;Jesús Santos;Alfonso Pinedo

  • Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir.

    Eugenia Vispo;Pablo Barreiro;Juan A Pineda;José A Mira

  • Pretransplant interferon-γ secretion by CMV-specific CD8+ T cells informs the risk of CMV replication after transplantation.

    S. Cantisán;R. Lara;M. Montejo;J. Redel

  • Transmission between HIV-infected patients of multidrug-resistant tuberculosis caused by Mycobacterium bovis.

    Samper S;Martín C;Pinedo A;Rivero A

  • Clinical epidemiology of Stenotrophomonas maltophilia colonization and infection: a multicenter study.

    Maria Dolores Del Toro;Jesus Rodriguez-Bano;Marta Herrero;Antonio Rivero

  • Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial.

    Federico Pulido;Esteban Ribera;María Lagarde;Ignacio Pérez-Valero

  • Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial.

    Chloe Orkin;Jean-Michel Molina;Eugenia Negredo;José R Arribas

  • Gentamicin therapy for sepsis due to carbapenem-resistant and colistin-resistant Klebsiella pneumoniae

    Marcelino Gonzalez-Padilla;Julián Torre-Cisneros;Julián Torre-Cisneros;Francisco Rivera-Espinar;Antonio Pontes-Moreno

  • Benefits From Sustained Virologic Response to Pegylated Interferon Plus Ribavirin in HIV/Hepatitis C Virus–Coinfected Patients With Compensated Cirrhosis

    José A. Mira;Antonio Rivero-Juárez;Luis F. López-Cortés;José A. Girón-González

  • Visceral leishmaniasis in HIV-1-infected individuals: a common opportunistic infection in Spain?

    Medrano Fj;Hernández-Quero J;Jiménez E;Pineda Ja

Frequent Co-Authors

Juan A. Pineda
Juan A. Pineda Spanish National Research Council
Jose R. Arribas
Jose R. Arribas Hospital Universitario La Paz
Pere Domingo
Pere Domingo Autonomous University of Barcelona
Santiago Moreno
Santiago Moreno Hospital Universitario Ramón y Cajal
Hernando Knobel
Hernando Knobel Autonomous University of Barcelona
Juan Berenguer
Juan Berenguer Hospital General Universitario Gregorio Marañón
José E. P. Santos
José E. P. Santos University of Florida
Federico Pulido
Federico Pulido Complutense University of Madrid
Ignacio García-Bocanegra
Ignacio García-Bocanegra University of Córdoba
Rafael Solana
Rafael Solana University of Córdoba

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in expanding their expertise beyond microbiology, exploring related online degrees offers flexible and valuable career options. Health Information Management (HIM) is a growing field closely tied to healthcare, and pursuing a cahiim accredited him degree online ensures quality education and industry recognition.

For those seeking quicker entry into the healthcare sector, options like the fastest online medical billing and coding certificate programs provide a pathway to certification within months, enabling graduates to contribute to essential healthcare administration tasks.

Moreover, understanding what medical degrees online that pay well are available can help students align their studies with high-demand, well-compensated careers. This is especially useful for those aiming for clinical or specialized roles through distance learning.

Public health is another vital area connected to microbiology. Many universities now offer online mph programs easy to get into, making advanced education in epidemiology and health policy accessible to a wider audience.

Considering these related online degrees can enhance career flexibility, open new job opportunities, and complement a strong foundation in microbiology.

Best Scientists Citing Antonio Rivero

Trending Scientists

Recently Published Articles